GlassScriptPhysician profile
Robert J Talamo
NPI 1083722946
$2,611.54
in general payments reported to CMS, 2019-2025
25 companies · $20.45 in 2025
The $20.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $830 · 2021: $426 · 2022: $40.73 · 2023: $23.66 · 2024: $17.23 · 2025: $20.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $425.04 | 2019-2022 | |
| Abbvie INC. | $422.77 | 2019-2023 | Vraylar |
| Pfizer INC. | $323.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.30 | 2019-2021 | |
| Amarin Pharma, INC. | $117.98 | 2019-2020 | |
| Astellas Pharma US INC | $114.40 | 2019-2020 | |
| Allergan, INC. | $104.66 | 2019-2020 | |
| Lilly USA, LLC | $95.71 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $94.28 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $88.33 | 2021 | |
| Amgen INC. | $78.51 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $77.90 | 2019-2020 | |
| Shire North American Group INC | $66.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.15 | 2019 | |
| Daiichi Sankyo INC. | $54.76 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.93 | 2020-2021 | |
| Ardelyx, INC. | $37.68 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $29.47 | 2019-2020 | |
| Novo Nordisk INC | $28.62 | 2020-2021 | |
| Sanofi Pasteur INC. | $26.83 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $21.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.07 | 2019 | |
| Assertio Therapeutics, INC. | $15.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.28 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Talamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.